Corcept Therapeutics (CORT) Tops Q2 EPS by 6c; Raises Rev Outlook
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $112.44 +0.73%
Revenue Growth %: +54.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +54.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.13, $0.06 better than the analyst estimate of $0.07. Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.53 million.
2017 revenue guidance increased by $20 million, to $145-155 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- United Natural Foods (UNFI) Tops Q4 EPS by 8c ; Offers Guidance
- GE Aerospace to acquire Consolidated Precision in $11.75b deal
- HSBC explains why risk assets continue to ignore every negative catalyst
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
